Aloxi and Keppra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aloxi (palonosetron hydrochloride) and Keppra (levetiracetam). Common drug interactions include hypoaesthesia among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Aloxi and Keppra. It is created by eHealthMe based on reports of 65 people who take the same drugs from the FDA, and is updated regularly.

What is Aloxi?

Aloxi has active ingredients of palonosetron hydrochloride. eHealthMe is studying from 9,072 Aloxi users. Check the latest studies of Aloxi.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

On Jul, 18, 2026

65 people who take Aloxi and Keppra together, and have interactions are studied.

What are the common drug interactions of Aloxi and Keppra, by gender? *:

female:

Hypoaesthesia (reduced sense of touch or sensation)
Nausea (feeling of having an urge to vomit)
Dehydration (dryness resulting from the removal of water)
Febrile neutropenia (fever with reduced white blood cells)
Malignant neoplasm progression (cancer tumour came back)
Neutropenia (an abnormally low number of neutrophils)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Thrombocytopenia (decrease of platelets in blood)
Abdominal distension
Anaemia (lack of blood)

male:

Death
Fatigue (feeling of tiredness)
Sepsis syndrome (a clinical condition of blood infection)
Syncope (loss of consciousness with an inability to maintain postural tone)
Asthenia (weakness)
Confusional state
Hypotension (abnormally low blood pressure)
Disease progression
Renal disorder (kidney disease)
Acute respiratory failure

What are the common drug interactions of Aloxi and Keppra, by age (0-1 to 60+)? *:

0-1:

Myelosuppression (a decrease in the production of blood cells)

2-9:

Cerebral hypoperfusion (a condition in which the brain doesn't get enough blood)
Encephalitis (inflammation of the brain)
Hydrocephalus (water on the brain)
Hypokalaemia (low potassium)
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood)
Lipase increased
Respiratory failure (inadequate gas exchange by the respiratory system)

10-19:

Acute respiratory failure
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Depressed level of consciousness
Dyspnoea (difficult or laboured respiration)
Febrile neutropenia (fever with reduced white blood cells)
Haemorrhage intracranial (bleeding within the skull)
Hypotension (abnormally low blood pressure)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
Failure to thrive (inadequate weight gain and physical growth in children)

20-29:

Alopecia (absence of hair from areas of the body)
Asthenia (weakness)
Bone marrow failure
Confusional state
Death
Decreased appetite
Dehydration (dryness resulting from the removal of water)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Diarrhoea
Fatigue (feeling of tiredness)

30-39:

n/a

40-49:

Chills (felling of cold)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Diarrhoea
Emotional distress
Fall
Gait disturbance
Glioblastoma (most common and most aggressive malignant primary brain tumour in humans)
Headache (pain in head)
Hypoaesthesia (reduced sense of touch or sensation)
Hypotension (abnormally low blood pressure)

50-59:

Death
Febrile neutropenia (fever with reduced white blood cells)
Confusional state
Cough
Lung infection
Malaise (a feeling of general discomfort or uneasiness)
Pain in extremity
Rash
Abdominal pain
Back pain

60+:

Syncope (loss of consciousness with an inability to maintain postural tone)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Dizziness
Pyrexia (fever)
Thrombocytopenia (decrease of platelets in blood)
Vomiting
Brain neoplasm (tumour of brain)
Cough
Delirium (wild excitement)
Disease progression

What are the existing conditions these people have? *

Brain Neoplasm Malignant (brain cancer tumour): 17 people, 26.15%
High Blood Pressure: 16 people, 24.62%
Stress And Anxiety: 15 people, 23.08%
Pain: 11 people, 16.92%
Anaemia (lack of blood): 11 people, 16.92%
Diabetes: 11 people, 16.92%
Nausea (feeling of having an urge to vomit): 10 people, 15.38%
Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 10 people, 15.38%
Constipation: 9 people, 13.85%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 8 people, 12.31%

* Approximation only. Some reports may have incomplete information.

Do you take Aloxi and Keppra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously